Olmesartan Medoxomil Krka

Olmesartan medoxomil, the active ingredient in Olmesartan Medoxomil Krka, is an angiotensin II receptor blocker presented as a tablet for oral use. It is employed in the management of hypertension in adult patients. GNH USA supplies Olmesartan Medoxomil Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmesartan Medoxomil Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan medoxil acts on the renin‑angiotensin system to lower blood pressure in several cardiovascular contexts.

- Hypertension: helps achieve target blood pressure and reduces cardiovascular risk. - Heart failure: used as part of combination therapy to improve symptoms and outcomes. - Diabetic nephropathy: slows progression of kidney damage associated with diabetes. - Post‑myocardial infarction: contributes to long‑term blood pressure control after an acute event. - Stroke prevention: aids in secondary prevention by maintaining optimal blood pressure levels.

Olmesartan medoxomil may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Nasal congestion - Diarrhoea - Upper respiratory tract infection

Serious or Rare Side Effects: - Angio‑edema involving the face, lips or tongue - Severe hypotension - Acute kidney injury - Hyperkalemia - Liver enzyme elevations - Allergic skin reactions such as rash or urticaria

When prescribing Olmesartan medoxomil, clinicians should consider several safety aspects.

- Blood pressure monitoring: ensure adequate control without excessive drops. - Renal function assessment: evaluate baseline kidney function and monitor periodically. - Electrolyte balance: check serum potassium, especially if combined with potassium‑sparing agents. - Pregnancy: contraindicated in the second and third trimesters due to fetal toxicity. - Drug interactions: review concomitant medications for potential additive hypotensive effects. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Olmesartan medoxomil can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Aliskiren (combined use in diabetic patients is contraindicated). - Potassium‑sparing diuretics or supplements (risk of hyper‑kalemia). - Lithium (increased lithium levels and toxicity risk).

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (may reduce antihypertensive effect). - ACE inhibitors (combined use may increase risk of renal impairment and hyper‑kalemia). - Diuretics (additive blood‑pressure lowering effect, monitor for hypotension).